FDA advisory committee approves booster for individuals 65 and older and others at high risk for COVID-19

A Food and Drug Administration advisory committee voted unanimously on Friday to approve emergency use authorization for a Pfizer vaccine booster shot individuals 65 years and older and individuals of any age at high risk of severe COVID-19.

The booster would be given six months after the last regular dose.

Read the full post on News Feed